| abstract |
Compounds of formula (I) wherein R?1 and R2¿ are each independently F, Cl, Br, CH¿3?, CH2CH3 or CF3; R?3¿ is H, CH¿3? or CH2CH3; and X is a 5-membered heterocyclic group containing up to four nitrogen atoms, attached via a nitrogen atom, the said group being optionally benzofused and/or substituted by C1-C6 alkyl or (CH2)nNR?4R5¿, wherein n is an integer from 1 to 5 and R?4 and R5¿ are each independently H, C¿1?-C6 alkyl, C3-C6 cycloalkyl or C1-C4 alkyl substituted by phenyl or pyridyl, or R?4 and R5¿ are linked to form, together with the nitrogen atom to which they are attached, a pyrrolidine, piperidine, piperazine, N-(C¿1?-C4 alkyl) piperazine, morpholine or azepine group; and their pharmaceutically acceptable salts, are NMDA antagonists of utility in the treatment of acute neurodegenerative disorders, e.g. arising from stroke or traumatic head injury and in chronic neurological disorders, e.g. senile dementia and Alzheimer's disease. |